Already indicated for refractory forms of myasthenia gravis, eculizumab (Soliris®) has been shown to be effective in two other indications:
- French clinicians, including experts from the Institute, achieved complete and rapid remission in two patients with dermatomyositis when eculizumab was administered in addition to immunosuppressive therapies. The two young women did not relapse after four years or 18 months of treatment,
- an Italian team observed a significant improvement in the clinical condition of a 73-year-old man with myasthenia gravis with autoantibodies directed against the acetylcholine receptor (anti-AChR) and presenting with a myasthenic crisis after 15 days of treatment.
